ClinicalTrials.gg
RecruitingNCT05759078INFERRCTUpdated Jul 30, 2025

Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion

A Phase 4 interventional study of Ferinject and Sodium Chloride 0.9% Inj in Myocardial Infarction, Acute, sponsored by Wroclaw Medical University. Recruiting at 43 sites in Poland. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-07-30.

Sponsored by Wroclaw Medical University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Sep 2022, registered Jan 2023).
  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 89 studies in Myocardial Infarction with a site in Poland — 17 open to participants now, 20 under way, 5 of them phase 3. Myocardial Infarction · Poland.

Planned enrollment
40th of 77
1,000 · median 1,012
Started
2022
with 1 other
Phase 4
13 of 89
4 open now
Primary completion
2026-12
later than 3 of 19 live
Registered
74th of 89
by date
Lead sponsor
3 of 89
Wroclaw Medical University

Among the 89 studies in Myocardial Infarction with a site in Poland, this one is the 40th largest by planned enrollment of the 77 interventional ones that give a count, is one of 2 that started in 2022, is one of 13 in phase 4, reaches primary completion later than 3 of the 19 other live ones, and was the 74th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

17 of the 89 studies in Myocardial Infarction with a site in Poland are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Myocardial Infarction with a site in Poland, or all of them as a file.
02

Study summary

Non-commercial, multicentre, randomised, double-blind, parallel group, placebo-controlled clinical trial. Eligible patients were randomly assigned (1:1) using a secure, central, interactive, web-based response system, to intervention FCM or placebo arm. Time of observation: minimum of 8 months up to a maximum of 36 months.

Primary Study Objective: Primary:

Evaluation of the effect of i.v. FCM treatment compared with placebo on the risk of death, the risk of heart failure events (HFE*) (number of events and time to first event), NTproBNP concentration and the change in quality of life (QoL) assessed using EQ-5D during the follow-up up to 36-months in patients with recent AMI and ID (with an implementation of a win ratio approach in a hierarchical descending order).

*HFE: unplanned hospitalization for HF (including unplanned visit at emergency department due to HF), ambulatory significant intensification of diuretic therapy (either starting i.v. loop diuretic or more than doubling oral loop diuretic dose or de novo initiation of oral loop diuretic therapy due to HF signs/symptoms).

03

Conditions studied

  • Myocardial Infarction, Acute

Keywords

  • Myocardial infarction
  • acute
  • iron deficiency
  • Infusion
  • ferric carboxymaltose
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years;
  2. Diagnosis of AMI (STEMI or NSTEMI) up to 4 weeks (28 days) before randomisation
  3. Presence of iron deficiency (ID) defined as transferrin saturation TSAT\<20% assessed within up to 4 weeks (28 days) before randomisation;
  4. Presence of ≥3 factors (confirmed within up to 4 weeks before randomisation) (note: at least one of a-c must be present):

    1. ≤50%;
    2. NT-proBNP ≥400 pg/mL for subjects in sinus rhythm and NT-proBNP ≥800 pg/mL for subjects with atrial fibrillation;
    3. Clinical features of congestion/volume overload (including Killip class II or more) requiring i.v. loop diuretic use;
    4. Diagnosis of diabetes mellitus (also de novo diagnosis);
    5. Diagnosis of atrial fibrillation (any time in the past or de-novo diagnosis);
    6. Multivessel coronary disease (regardless of completeness of revascularisation during an index AMI);
    7. Not complete revascularisation or/and no reperfusion (during an index AMI);
    8. History of AMI (despite an index AMI);
    9. \<60 mL/min/1.73m2; 1. Age ≥70 years.
  5. Written

Exclusion criteria

Exclusion criteria:

  1. Subject temperature >38 ͦ C or any infection requiring antibiotic therapy within 48 hours prior to randomisation;
  2. Severe, symptomatic valve disorder;
  3. Urgent hospitalisation for whatever reasons (percutaneous/surgical procedure requiring hospitalisation within 4 weeks prior to randomisation).
  4. Body weight \<50 kg;
  5. \<8 g/dL or >15,5 g/dL;
  6. Serum ferritin >400 ng/mL;
  7. Active gastroenteral bleeding;
  8. Known to any of the administered preparations;
  9. Treatment with erythropoiesis stimulating factors, i.v. iron therapy or blood transfusion within 6 months prior to randomisation;
  10. Subject has known active of any organ system, i.e., clinical evidence of current malignancy or not in stable remission for at least 3 years since completion of last treatment with exception of non-invasive basal cell carcinoma, squamous cell carcinoma of the skin or cervical intra-epithelial neoplasia;
  11. Documented liver diseases;
  12. Participation in a device or drug trial within 3 months prior to randomisation or 5 half-lives, whichever period is longer, prior to the screening visit;
  13. Pregnancy or lactation;
  14. Any situation that may prevent the test from being performed in accordance with the protocol, or the consent of the investigator to be given in writing, including alcohol, drugs or any other substance overuse or addiction.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    Active

    an i.v. 15-minute infusion of 20 mL Ferinject (containing 1000 mg of FCM) diluted in 50 mL of NaCl 0.9%

    Drug: Ferinject

  • Placebo comparator
    Placebo

    70 mL of i.v. NaCl 0.9% infusion

    Drug: Sodium Chloride 0.9% Inj

Interventions

  • DrugFerric carboxymaltoseStudies of Ferric carboxymaltoseFerric carboxymaltose pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The first dose of either FCM will be administered during the first visit on the day of randomisation (V1). Then, the participants will be reassessed at 4, 8, 12, 18, 24 and 30 months (visits V2, V3, V4, V5, V6, V7). If safety criteria are not fulfilled, a patient in the active study arm will receive i.v. NaCl 0.9% during the particular visit.

  • DrugSodium Chloride 0.9% Inj

    The first dose of placebo will be administered during the first visit on the day of randomisation (V1). Then, the participants will be reassessed at 4, 8, 12, 18, 24 and 30 months (visits V2, V3, V4, V5, V6, V7).

06

What researchers measure

Primary outcomes

  1. Time to all-cause death assessed up to maximum 36-months follow-up;

    Defined as: (with an implementation of a win ratio approach in a hierarchical descending order): 1. Time to all-cause death assessed up to maximum 36-months follow-up; 2. Number of HFE assessed up to maximum 36-months follow-up; 3. Time to first HFE assessed up to maximum 36-months follow-up; 4. Changes in serum NT-proBNP concentration from the start of the follow-up to the end of participation in the study assessed as the area under the curve; 5. Changes in quality of life (QoL) measured using the EQ-5D questionnaire from the start of the follow-up to the end of participation in the study assessed as the area under the curve. * HFE: unplanned hospitalization for HF (including unplanned visit at emergency department due to HF), ambulatory significant intensification of diuretic therapy (either starting i.v. loop diuretic or more than doubling oral loop diuretic dose or de novo initiation of oral loop diuretic therapy due to HF signs/symptoms).

    Time frame: up to 36 months

  2. Number of HFE assessed up to maximum 36-months follow-up

    Number of HFE

    Time frame: up to 36 months

  3. Time to first HFE assessed up to maximum 36-months follow-up

    Time to first HFE

    Time frame: up to 36 months

  4. Changes in serum NT-proBNP concentration from the start of the follow-up to the end of participation in the study assessed as the area under the curve

    Changes in serum NT-proBNP

    Time frame: up to 36 months

  5. Changes in quality of life (QoL) measured using the EQ-5D questionnaire from the start of the follow-up to the end of participation in the study assessed as the area under the curve

    Changes in quality of life

    Time frame: up to 36 months

Secondary outcomes

  1. First unplanned HF hospitalisation or unplanned visit at emergency department due to HF or CV death during the follow-up (time-to-event model)

    First unplanned HF hospitalisation or unplanned visit at emergency

    Time frame: up to 36 months

  2. All unplanned HF hospitalisations and unplanned visit at emergency department due to HF and CV death during the follow-up (recurrent event model);

    All unplanned HF hospitalisations and unplanned visit at emergency

    Time frame: up to 36 months

  3. All unplanned HF hospitalisations and unplanned visit at emergency department due to HF during the follow-up (recurrent event model)

    All unplanned HF hospitalisations and unplanned visit at emergency department

    Time frame: up to 36 months

  4. All unplanned HF hospitalisations during the follow-up (recurrent event model);

    All unplanned HF hospitalisations

    Time frame: up to 36 months

  5. CV death during the follow-up

    CV death

    Time frame: up to 36 months

Other outcomes

  1. First unplanned CV hospitalisation or CV death during the follow-up (time-to-event model);

    First unplanned CV hospitalisation or CV death during the follow-up

    Time frame: up to 36 months

  2. All unplanned CV hospitalisations and CV death during the follow-up (recurrent event model);

    All unplanned CV hospitalisations and CV death during the follow-up

    Time frame: up to 36 months

  3. All unplanned CV hospitalisations during the follow-up (recurrent event model);

    All unplanned CV hospitalisations during the follow-up (recurrent event model);

    Time frame: up to 36 months

  4. Non-CV death during the follow-up

    Non-CV death during the follow-up

    Time frame: up to 36 months

  5. All-cause death during the follow-up up

    All-cause death during the follow-up

    Time frame: up to 36 months

  6. Ambulatory significant intensification of diuretic therapy during the follow-up

    Ambulatory significant intensification of diuretic therapy (either starting i.v. loop diuretic or more than doubling oral loop diuretic dose or de novo initiation of oral loop diuretic therapy due to HF signs/symptoms) during the follow-up.

    Time frame: up to 36 months

  7. Changes in serum NT-proBNP concentration assessed as the area under the curve during the follow-up;

    Changes in serum NT-proBNP concentration assessed as the area under the curve during the follow-up;

    Time frame: up to 36 months

  8. Changes in quality of life (QoL) measured using the EQ-5D questionnaire assessed as the area under the curve during the follow-up;

    Changes in quality of life (QoL) measured using the EQ-5D questionnaire assessed as the area under the curve during the follow-up;

    Time frame: up to 36 months

  9. Cost-effectiveness measures during the follow-up

    Cost-effectiveness measures during the follow-up.

    Time frame: up to 36 months

07

Study locations

31 of 43 sites recruiting
  • Vitamed Bydgoszcz
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-079, Poland
    Recruiting
    • · Contact52 347 88 15
  • Regionalny Szpital Specjalistyczny im. dr Wł. Biegańskiego w Grudziądzu
    Grudziądz, Kuyavian-Pomeranian Voivodeship 86-300, Poland
    Recruiting
    • · Contact56 641 44 44
  • Wojewódzki Szpital Zespolony im. L. Rydygiera w Toruniu
    Torun, Kuyavian-Pomeranian Voivodeship 87-100, Poland
    Recruiting
    • · Contact56 679 31 00
  • Polsko-Amerykańskie Kliniki Serca Małopolskie Centrum Sercowo-Naczyniowe
    Chrzanów, Lesser Poland Voivodeship 32-500, Poland
    Recruiting
    • · Contact32 758 69 00
  • Szpital Specjalistyczny im. SS im. Henryka Klimontowicza w Gorlicach
    Gorlice, Lesser Poland Voivodeship 38-300, Poland
    Terminated

    Not enrolling at this site — choose another above.

  • Szpital Specjalistyczny im. J. Dietla w Krakowie
    Krakow, Lesser Poland Voivodeship 31-121, Poland
    Recruiting
    • · Contact12 68 76 200
  • Podhalański Szpital Specjalistyczny im. Jana Pawła II w Nowym Targu
    Nowy Targ, Lesser Poland Voivodeship 34-400, Poland
    Terminated

    Not enrolling at this site — choose another above.

  • Medicome Sp. z o.o.
    Oświęcim, Lesser Poland Voivodeship 32-600, Poland
    Recruiting
    • · Contact48 505 121 703
  • Szpital Wojewódzki im. św. Łukasza SP ZOZ w Tarnowie
    Tarnów, Lesser Poland Voivodeship 33-100, Poland
    Terminated

    Not enrolling at this site — choose another above.

  • Zespół Opieki Zdrowotnej w Kłodzku
    Kłodzko, Lower Silesian Voivodeship 57-300, Poland
    Recruiting
    • · Contact74 865 12 00
  • Uniwersytecki Szpital kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu
    Wroclaw, Lower Silesian Voivodeship 50-556, Poland
    Recruiting
    • · Contact71 736 42 76
  • 4. Wojskowy Szpital Kliniczny z Polikliniką SP ZOZ
    Wroclaw, Lower Silesian Voivodeship 50-981, Poland
    Terminated

    Not enrolling at this site — choose another above.

  • Dolnośląski Szpital Specjalistyczny im. T. Marciniaka - Centrum Medycyny Ratunkowej
    Wroclaw, Lower Silesian Voivodeship 54-049, Poland
    Recruiting
    • · Contact71 306 44 19
  • Wielospecjalistyczny Szpital SP ZOZ w Zgorzelcu
    Zgorzelec, Lower Silesian Voivodeship 59-900, Poland
    Recruiting
    • · Contact75 772 29 00
  • 4Cardia Sp. z o.o.
    Kraśnik, Lublin Voivodeship 23-204, Poland
    Terminated

    Not enrolling at this site — choose another above.

  • 1. Wojskowy Szpital Kliniczny z Polikliniką Samodzielny Publiczny Zakład Opieki Zdrowotnej w Lublinie
    Lublin, Lublin Voivodeship 20-049, Poland
    Terminated

    Not enrolling at this site — choose another above.

  • Ośrodek Kardiologii Inwazyjnej IKARDIA Sp. z o.o.
    Nałęczów, Lublin Voivodeship 24-140, Poland
    Terminated

    Not enrolling at this site — choose another above.

  • Szpital Uniwersytecki imienia Karola Marcinkowskiego w Zielonej Górze Sp. z o. o.
    Zielona Góra, Lubusz Voivodeship 65-046, Poland
    Recruiting
    • · Contact68 329 62 00
  • Centralny Szpital Kliniczny MSWiA w Warszawie
    Warsaw, Masovian Voivodeship 02-507, Poland
    Terminated

    Not enrolling at this site — choose another above.

  • Mazowiecki Szpital Bródnowski Sp. z o.o.
    Warsaw, Masovian Voivodeship 03-242, Poland
    Recruiting
    • · Contact22 326 52 26
  • Wojskowy Instytut Medyczny - Państwowy Instytut Badawczy
    Warsaw, Masovian Voivodeship 04-349, Poland
    Recruiting
    • · Contact26 181 76 66
  • Polsko-Amerykańskie Kliniki Serca Centrum Sercowo-Naczyniowe w Kędzierzynie Koźlu
    Kędzierzyn-Koźle, Opole Voivodeship 47-200, Poland
    Recruiting
    • · Contact77 472 25 65
  • Centrum Kardiologii w Kluczborku Scanmed S.A.
    Kluczbork, Opole Voivodeship 46-200, Poland
    Recruiting
    • · Contact77 410 82 18
  • Uniwersytecki Szpital Kliniczny w Opolu
    Opole, Opole Voivodeship 45-401, Poland
    Recruiting
    • · Contact77 452 07 45
  • Centrum Opieki Medycznej w Jarosławiu
    Jarosław, Podkarpackie Voivodeship 37-500, Poland
    Recruiting
    • · Contact16 621 54 21
  • Centrum Kardiologii Inwazyjnej Elektroterapii i Angiologii w Krośnie
    Krosno, Podkarpackie Voivodeship 38-400, Poland
    Terminated

    Not enrolling at this site — choose another above.

  • Uniwersyteckim Centrum Kliniczne w Gdańsku
    Gdansk, Pomeranian Voivodeship 80-952, Poland
    Recruiting
    • · Contact58 349 20 00
  • Polsko-Amerykańskie Kliniki Serca Centrum Kardiologiczno-Angiologiczne w Sztumie
    Sztum, Pomeranian Voivodeship 82-400, Poland
    Recruiting
    • · Contact55 625 92 20
  • Wojewódzki Szpital Specjalistyczny im. Janusza Korczaka w Słupsku Sp. z o.o.
    Słupsk, Pomeranian Voivodeship 76-200, Poland
    Terminated

    Not enrolling at this site — choose another above.

  • Polsko-Amerykańskie Kliniki Serca Centrum Kardiologii i Kardiochirurgii w Bielsku-Białej
    Bielsko-Biala, Silesian Voivodeship 43-316, Poland
    Recruiting
    • · Contact33 828 93 70
  • Polsko-Amerykańskie Kliniki Serca, X Oddział Kardiologii Inwazyjnej, Elektrofizjologii i Elektrostymulacji w Tychach
    Tychy, Silesian Voivodeship 43-100, Poland
    Recruiting
    • · Contact32 758 67 00
  • Samodzielny Publiczny Szpital Kliniczny nr 2 PUM w Szczecinie
    Szczecin, West Pomeranian Voivodeship 70-111, Poland
    Recruiting
    • · Contact91 466 10 00
  • Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie
    Krakow, Poland
    Recruiting
  • Wojewódzki Szpital Specjalistyczny w Legnicy
    Legnica, Poland
    Recruiting
  • Samodzielny Publiczny Zespół Zakładów Opieki Zdrowotnej im. dr Wojciecha Oczko w Przasnyszu
    Przasnysz, Poland
    Recruiting
  • Wojewódzki Szpital im. Św. Ojca Pio
    Przemyśl, Poland
    Recruiting
  • Szpital Specjalistyczny Ducha Świętego w Sandomierzu
    Sandomierz, Poland
    Terminated

    Not enrolling at this site — choose another above.

  • Medicover Sp z o.o.
    Warsaw, Poland
    Recruiting
  • Szpital Specjalistyczny w Zabrzu Sp. z o.o.
    Zabrze, Poland
    Recruiting
  • Śląskie Centrum Chorób Serca w Zabrzu
    Zabrze, Poland
    Recruiting
  • Nzoz Salusmed
    Lodz, Łódź Voivodeship 91-002, Poland
    Recruiting
    • · Contact42 671 34 34
  • Centralny Szpital Kliniczny Uniwersytetu Medycznego w Łodzi
    Lodz, Łódź Voivodeship 92-213, Poland
    Recruiting
    • · Contact42 201 42 40
  • Polsko-Amerykańskie Kliniki Serca Centrum Kardiologii Med-Pro
    Zgierz, Łódź Voivodeship 95-100, Poland
    Terminated

    Not enrolling at this site — choose another above.

08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Dec 2026, 51 months after the start.

Of 83 non-industry phase 4 interventional studies under Myocardial Infarction, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 78. This study's planned 51 months is above that.

Counting every sponsor, half of 87 studies reached it within 42 months; a quarter within 22 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2023
First posted
Mar 8, 2023
StartActual
Sep 22, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05759078
Lead sponsor
Wroclaw Medical University
Responsible party
Sponsor
First posted
Mar 8, 2023
Start date
Sep 22, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 30, 2025

Study contacts

Marta Duda-Sikuła
Contact
marta.duda-sikula@umw.edu.pl
717840696 ext. 0048
Julia Raińczuk
Contact
julia.rainczuk@umw.edu.pl
717840697
Piotr Ponikowski
principal investigator · Wroclaw Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion